[{"data":1,"prerenderedAt":239},["ShallowReactive",2],{"$f35shjsqiwlnhj":3},{"schema":4,"slug":5,"series":6,"series_slug":7,"name":8,"year":9,"therapeutic_area":10,"generated_at":11,"counts":12,"top_targets":23,"top_modalities":57,"top_diseases":84,"top_companies":114,"key_results":141,"trends":228,"previous_editions":237,"comparison":223,"highlighted_classes":238},1,"ats-2026","ATS","ats","ATS International Conference 2026",2026,"Pulmonology","2026-11-05T22:19:09Z",{"abstracts":13,"drug_linked":14,"companies":15,"by_phase":16},7161,1751,230,{"Phase 1":17,"Phase 1\u002F2":18,"Phase 2":19,"Phase 4":20,"Phase 2\u002F3":21,"Phase 3":22},25,4,41,9,5,71,[24,28,32,35,38,41,45,48,51,54],{"name":25,"count":26,"share":27},"GR",141,8,{"name":29,"count":30,"share":31},"ADRB2",52,3,{"name":33,"count":34,"share":31},"CD20",51,{"name":36,"count":37,"share":31},"IL4R",50,{"name":39,"count":40,"share":31},"IL13RA1",47,{"name":42,"count":43,"share":44},"PDCD1",42,2,{"name":46,"count":47,"share":44},"IL-5",37,{"name":49,"count":50,"share":44},"CYP51A1",35,{"name":52,"count":53,"share":44},"ACVR2A",31,{"name":55,"count":56,"share":44},"Activin A",30,[58,62,66,70,73,76,79,81],{"name":59,"count":60,"share":61},"Small molecules",1210,69,{"name":63,"count":64,"share":65},"Monoclonal antibodies",393,22,{"name":67,"count":68,"share":69},"Non-antibody therapeutic proteins",120,7,{"name":71,"count":72,"share":18},"Peptides",68,{"name":74,"count":75,"share":31},"Carbohydrate, lipid and polymer therapeutics",44,{"name":77,"count":78,"share":44},"Blood, tissue and cell-derived products",34,{"name":80,"count":65,"share":4},"Oligonucleotide and RNA therapeutics",{"name":82,"count":83,"share":4},"Non-radioactive imaging and contrast agents",18,[85,89,92,96,99,102,105,107,110,112],{"name":86,"count":87,"share":88},"asthma",172,10,{"name":90,"count":91,"share":27},"chronic obstructive pulmonary disease (COPD)",143,{"name":93,"count":94,"share":95},"idiopathic pulmonary fibrosis (IPF)",111,6,{"name":97,"count":98,"share":21},"interstitial lung disease (ILD)",89,{"name":100,"count":101,"share":21},"pulmonary arterial hypertension (PAH)",83,{"name":103,"count":104,"share":21},"pulmonary fibrosis (PF)",80,{"name":106,"count":72,"share":18},"acute respiratory distress syndrome (ARDS)",{"name":108,"count":109,"share":18},"pulmonary hypertension (PH)",62,{"name":111,"count":43,"share":44},"cystic fibrosis (CF)",{"name":113,"count":19,"share":44},"pneumonia",[115,118,121,124,126,129,131,134,136,139],{"name":116,"count":117,"share":20},"Pfizer",165,{"name":119,"count":120,"share":95},"Merck",104,{"name":122,"count":123,"share":21},"AstraZeneca",91,{"name":125,"count":98,"share":21},"GSK",{"name":127,"count":128,"share":21},"Genentech",88,{"name":130,"count":101,"share":21},"Bristol Myers Squibb",{"name":132,"count":133,"share":31},"Bayer",59,{"name":135,"count":30,"share":31},"Sanofi",{"name":137,"count":138,"share":31},"Johnson & Johnson",48,{"name":140,"count":40,"share":31},"Regeneron Pharmaceuticals",[142,150,156,163,171,178,184,190,199,205,212,219],{"title":143,"drug":144,"company":146,"phase":147,"disease":100,"finding":148,"url":149},"ADVANCE Outcomes: A Phase 3, Double-blind, Placebo-controlled Clinical Trial Of Ralinepag For The Treatment Of Pulmonary Arterial Hypertension",{"name":145,"slug":145},"ralinepag","United Therapeutics","Phase 3","Clinical worsening occurred in 18% (n = 64) of the ralinepag group and 36% (n = 121) of the placebo group (hazard ratio, 0.45; 95% confidence interval, 0.33-0.62; p \u003C 0.0001).","https:\u002F\u002Fdoi.org\u002F10.1093\u002Fajrccm\u002Faamag286.013",{"title":151,"drug":152,"company":122,"phase":147,"disease":86,"finding":154,"url":155},"Efficacy and Safety of Tezepelumab Versus Placebo in Reducing OCS Use in OCS-Dependent Patients With Severe Asthma: Results From the Phase 3 Sunrise Study",{"name":153,"slug":153},"tezepelumab","The odds of reaching a category of greater percent OCS reduction at week 28 were higher with tezepelumab than placebo (cumulative odds ratio: 2.93 [95% confidence interval: 1.43, 6.03]; p=0.003).","https:\u002F\u002Fdoi.org\u002F10.1093\u002Fajrccm\u002Faamag162.413",{"title":157,"drug":158,"company":119,"phase":147,"disease":160,"finding":161,"url":162},"Efficacy and Safety of Sotatercept in Patients With Pulmonary Arterial Hypertension (PAH) Associated With Connective Tissue Disease (CTD): A Pooled Analysis From STELLAR, ZENITH, and HYPERION",{"name":159,"slug":159},"sotatercept","connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH)","For major morbidity\u002Fmortality events, sotatercept reduced the risk of a first event versus placebo (HR 0.39 [95% CI: 0.19-0.83]; P=0.006), with 12 sotatercept-treated versus 25 placebo-treated participants having ≥1 event.","https:\u002F\u002Fdoi.org\u002F10.1093\u002Fajrccm\u002Faamag162.5479",{"title":164,"drug":165,"company":167,"phase":147,"disease":168,"finding":169,"url":170},"Efficacy and Safety of Oveporexton (TAK-861), an Oral Orexin Receptor 2 Agonist for the Treatment of Narcolepsy Type 1: Results From the Phase 3 Radiant Light Study",{"name":166,"slug":166},"oveporexton","Takeda","narcolepsy type 1 (NT1)","Most TEAEs with oveporexton were urinary frequency (43 [61.4%]), insomnia (40 [57.1%]), and urinary urgency (10 [14.3%]).","https:\u002F\u002Fdoi.org\u002F10.1093\u002Fajrccm\u002Faamag162.6476",{"title":172,"drug":173,"company":175,"phase":147,"disease":106,"finding":176,"url":177},"A Phase 3, Multicenter, Double-blind, Placebo Controlled Study of an Anti-TLR4 Antibody, Paridiprubart, in Adult Patients With Respiratory Distress on Invasive Mechanical Ventilation",{"name":174,"slug":174},"paridiprubart","Edesa Biotech","The adjusted rate of achieving ≥ 2-point reduction in WCSS was 38% (95% CI: 31%-45%) in the paridiprubart group and 27% (95% CI: 21%-33%) in the placebo group, for an adjusted difference in proportions of 11% (p \u003C 0.05).","https:\u002F\u002Fdoi.org\u002F10.1093\u002Fajrccm\u002Faamag162.237",{"title":179,"drug":180,"company":127,"phase":147,"disease":90,"finding":182,"url":183},"Astegolimab for Chronic Obstructive Pulmonary Disease (COPD) in Patients With a History of Frequent Exacerbations: The Phase III, Randomized, Double-blind, Placebo-controlled, Multicenter ARNASA Trial",{"name":181,"slug":181},"astegolimab","Astegolimab was well tolerated, with comparable proportions of patients experiencing ≥1 AE across the 3 study arms (Q2W, 83.2%; Q4W, 87.9%; placebo, 85.5%).","https:\u002F\u002Fdoi.org\u002F10.1093\u002Fajrccm\u002Faamag162.1747",{"title":185,"drug":186,"company":135,"phase":147,"disease":90,"finding":188,"url":189},"Efficacy and Safety of Itepekimab in Former Smokers With Chronic Obstructive Pulmonary Disease: AERIFY-1 and AERIFY-2 Trials",{"name":187,"slug":187},"itepekimab","Treatment-emergent adverse events occurred in 67.1% (itepekimab q2w), 68.2% (itepekimab q4w), and 68.4% (placebo) of patients in AERIFY-1 and in 64.3% (itepekimab q2w), 71.2% (itepekimab q4w), and 64.2% (placebo) of patients in AERIFY-2.","https:\u002F\u002Fdoi.org\u002F10.1093\u002Fajrccm\u002Faamag286.124",{"title":191,"drug":192,"company":195,"phase":147,"disease":196,"finding":197,"url":198},"Aroxybutynin and Atomoxetine (AD109) in Obstructive Sleep Apnea: A Pooled Analysis of the SynAIRgy and LunAIRo Phase 3 Trials",{"name":193,"slug":194},"AD109","ad109","Apnimed","obstructive sleep apnea hypopnea syndrome (OSAHS)","AD109 reduced AHI4 by ≥ 50% in 28.3% of participants (vs 17.7% with PBO; p \u003C 0.0001); a higher proportion of participants receiving AD109 achieved disease control (AHI4\u003C5; p \u003C 0.0001).","https:\u002F\u002Fdoi.org\u002F10.1093\u002Fajrccm\u002Faamag286.317",{"title":200,"drug":201,"company":125,"phase":147,"disease":90,"finding":203,"url":204},"Mepolizumab Reduces Type-2 COPD Exacerbations Requiring Systemic Corticosteroids in a Wide Spectrum of Patients: Pooled Results From Phase III Randomized Controlled Trials",{"name":202,"slug":202},"mepolizumab","The annualized rate of moderate\u002Fsevere exacerbations treated with SCS was significantly reduced by 25% with mepolizumab versus placebo (rate ratio [RR] [95% confidence interval (CI)]: 0.75 [0.67, 0.85]).","https:\u002F\u002Fdoi.org\u002F10.1093\u002Fajrccm\u002Faamag286.127",{"title":206,"drug":207,"company":125,"phase":147,"disease":209,"finding":210,"url":211},"Depemokimab Demonstrates Sustained Long-term Efficacy and Consistent Patient-reported Outcomes Over 2 Years in Patients With Type 2 Asthma Irrespective of Baseline Inhaled Corticosteroid Dose: An Integrated Analysis of the Phase III SWIFT-1\u002F-2 and the Open-label Extension AGILE Studies",{"name":208,"slug":208},"depemokimab","Th2 asthma (Th2)","In SWIFT-1\u002F-2 (N = 762), depemokimab reduced exacerbations by 54% versus placebo (rate ratio [95% CI]: 0.46 [0.36, 0.59]); in the depemokimab group, AER (95% CI) over 52 weeks was 0.36 (0.27, 0.48) for medium-dose ICS subgroup and 0.65 (0.53, 0.79) for high-dose ICS subgroup.","https:\u002F\u002Fdoi.org\u002F10.1093\u002Fajrccm\u002Faamag162.411",{"title":213,"drug":214,"company":122,"phase":147,"disease":216,"finding":217,"url":218},"Efficacy and Safety of Benralizumab in Chinese Patients With Severe Eosinophilic Asthma: 16-week Results From a Phase IIIb Study of Step-down Maintenance Therapy (step)",{"name":215,"slug":215},"benralizumab","eosinophilic asthma (EA)","Serious AEs occurred in 15.1% (76\u002F504) of patients, among which 2.4% (12\u002F504) were benralizumab-related.","https:\u002F\u002Fdoi.org\u002F10.1093\u002Fajrccm\u002Faamag162.480",{"title":220,"drug":221,"company":223,"phase":224,"disease":225,"finding":226,"url":227},"Randomized Phase 2\u002F3 Trial of an All-Oral Bedaquiline-Based Regimen for Refractory Mycobacterium Avium Complex (MAC) Lung Disease",{"name":222,"slug":222},"bedaquiline",null,"Phase 2\u002F3","Mycobacterium avium-intracellulare infection (MAI)","Serious adverse events were reported in 6.2% (4\u002F65) participants in the bedaquiline regimen and 3.1% (2\u002F64) participants in control up to Week 24.","https:\u002F\u002Fdoi.org\u002F10.1093\u002Fajrccm\u002Faamag286.343",{"summary":229,"bullets":231},[230],"Small molecules were the most frequent modality (69% of drug-linked abstracts). GR was the most frequent target (8%). Asthma was the most frequent disease (10%).",[232,233,234,235,236],"Pfizer had the largest company share (9% of drug-linked abstracts).","Monoclonal antibodies were the next most frequent modality (22%).","ADRB2 was the next most frequent target (3%).","Chronic obstructive pulmonary disease (COPD) was the next most frequent disease (8%).","Merck had the next largest company share (6%).",[],[],1793970603103]